Lilly has now submitted a new drug application (NDA) for orforglipron to the FDA for use in adults with obesity.
Takeda’s oral PsO candidate met its primary and secondary endpoints in two Phase III trials.
Galderma published the data in the Journal of the European Academy of Dermatology and Venereology.
The study protocol comprises dose-expansion and dose-escalation phases and aims to assess the efficacy and safety of QT-019B.
SGX945 was well-tolerated with no treatment-related adverse events.
Following the positive outcome, Pfizer and Astellas will seek approval of Padcev-Keytruda in MIBC regardless of a patient’s cisplatin eligibility.
